Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2 (CloroCOVID19)
Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial
Sponsor: Felipe Gomes Naveca
Listed as NCT04323527, this PHASE2 trial focuses on SARS-CoV Infection and Severe Acute Respiratory Syndrome (SARS) Pneumonia and remains completed. Sponsored by Felipe Gomes Naveca, it has been updated 7 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed
▶ Show 2 earlier versions
-
May 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE2
First recorded
Mar 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Felipe Gomes Naveca
- Fernando Fonseca de Almeida e Val
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
- Gisely Cardoso de Melo
- Jorge Souza Mendonça
- Ludmila Abrahão Hajjar
- Marcus Vinícius Guimarães de Lacerda
- Maria Paula Gomes Mourão
- Mayla Gabriela Silva Borba
- Wuelton Marcelo Monteiro
For direct contact, visit the study record on ClinicalTrials.gov .